ClinicalTrials.gg
Active, not recruitingNCT06680817Updated Oct 2, 2026

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

An observational study in Neovascular Age-related Macular Degeneration and Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Active, not recruiting at 59 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Primary conditionMacular EdemaRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Macular Edema
Why
  1. The study's listed conditions name Macular Edema, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hoffmann-La Roche · Observational

How we know

Updated Oct 2, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
875
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.

Started
2025
the only one that year
Observational
3 of 28
none open now
Registered
23rd of 28
by date

Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the only one that started in 2025, is one of 3 observational ones, and was the 23rd registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Macular Edema by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The FaReal study aims to evaluate the effectiveness, safety, clinical insights and treatment patterns in patients treated with faricimab, in neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in at least one eye, in real-world routine clinical practice over a 2-year patient follow-up period. Additionally, the FaReal study also aims to describe and evaluate health economic aspects of previous anti-VEGF treatments and current treatment with faricimab.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema

Browse trials for

04

In context

Macular Edema Reclassified

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

This study's planned enrollment of 875 is above the median of 71 across 127 observational studies indexed under Macular Edema.

Browse Macular Edema studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.

Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients being treated with faricimab approved for nAMD and DME in real-world, routine clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients receiving faricimab according to the local faricimab product label and who have initiated treatment with faricimab at time of the ICF signature date or no more than 3 months prior to the ICF signature date, in diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD) in at least one eye
  • Patients have received at least one faricimab treatment (the first dose) in the study eye
  • Patients should have available data for visual acuity (VA) and Central Subfield Thickness (CST) for the Baseline level (i.e. examinations to be performed at the index date or within 4 months prior to it)

Exclusion criteria

Exclusion Criteria:

  • Patient participation in any ophthalmology clinical trial that includes receipt of any ophthalmological investigational drug or procedure within the last 28 days prior to the ICF signature date
  • Concomitant participation in any interventional clinical study
  • Active ocular inflammation and/or suspected/active ocular infection in either eye
  • Patients treated with faricimab who have and are currently participating in patient support programs (PSP) that are Market Research and Patient Support Programs (MAP) including Post Trial Access Programs (PTAP) and Compassionate Use Programs (CUP)
  • Patients with non-ocular sight threatening disease which have an effect on the primary endpoint (e.g., apoplexia)
  • to the active substance or any of the of Vabysmo (as per label)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
875 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1: Faricimab for nAMD

    This cohort will be divided into two sub-cohorts based on eye treatment history: anti-VEGF treatment naive and anti-VEGF pre-treated.

    Drug: Faricimab

  • Cohort 2: Faricimab for DME

    This cohort will be divided into two sub-cohorts based on eye treatment history: anti-VEGF treatment naive and anti-VEGF pre-treated.

    Drug: Faricimab

Interventions

  • Faricimab will be administered as per local clinical practice and local labeling.

    Also known as: VABYSMO®, RO6867461, RG7716

07

What researchers measure

Primary outcomes

  1. Change in Visual Acuity from Index Date to 12 Months

    The index date is defined as the date of the first faricimab treatment injection in the eye.

    Time frame: Index Date and 12 months

Secondary outcomes

  1. Change in Visual Acuity from Index Date to 3, 6, and 24 Months

    Time frame: Index Date and 3, 6, and 24 months

  2. Change in Central Subfield Thickness (CST) from Index Date to 3, 6, 12, and 24 Months

    Time frame: Index Date and 3, 6, 12, and 24 months

  3. Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) Over Time

    Time frame: Index Date and 3, 6, 12, and 24 months

  4. Number of Faricimab Intravitreal Injections per Eye per Year

    Time frame: 12 and 24 months

  5. Number of Faricimab Intravitreal Injections in the Loading Phase for Participants who are anti-VEGF Treatment Naive or anti-VEGF pre-Treated

    Time frame: Approximately 4 months

  6. Total Number of Visits and Number of Visits With or Without Treatment Over Time

    Time frame: 3, 6, 12, and 24 months

  7. Cumulative Time Spent in Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other)

    Time frame: From Index Date to 24 months

  8. Percentage of Eyes With Treatment Switch from Faricimab by Reason for Switch in Participants who are anti-VEGF Treatment Naive or anti-VEGF pre-Treated

    Time frame: 3, 6, 12, and 24 months

  9. Percentage of Eyes Obtaining Treatment Intervals of Once Every 8, 12, or 16 Weeks or Other Intervals in Participants who are anti-VEGF Treatment Naive or anti-VEGF pre-Treated

    Time frame: 12 and 24 months

  10. Change in Visual Acuity from Index Date Over Time, According to Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other)

    Time frame: Index Date and 3, 6, 12, and 24 months

  11. Change in Visual Acuity from Index Date Over Time, According to Number of Intravitreal Treatments

    Time frame: Index Date and 3, 6, 12, and 24 months

  12. Change in Visual Acuity from Index Date Over Time, According to Total Number of Visits

    Time frame: Index Date and 3, 6, 12, and 24 months

  13. Change in Visual Acuity from Index Date Over Time, According to Treatment Intervals

    Time frame: Index Date and 3, 6, 12, and 24 months

  14. Change in Visual Acuity from Index Date Over Time, According to Type of anti-VEGF Pre-Treatment and Number of Previous Injections for Preceding Regimen at Index Date

    Time frame: Index Date and 3, 6, 12, and 24 months

  15. Change in Visual Acuity from Index Date Over Time, According to Length of Diagnosis of Disease at Index Date

    Time frame: Index Date and 3, 6, 12, and 24 months

  16. Number of Participants with at Least One Ocular Adverse Event

    Time frame: Approximately 2 years

  17. Number of Participants with at Least One Non-Ocular Adverse Event

    Time frame: Approximately 2 years

08

Study locations

59 sites
09

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jun 2027, 28 months after the start.

Of 44 observational studies under Macular Edema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 28 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Nov 8, 2024
StartActual
Feb 5, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
850→875
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Enrollment 850→875
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06680817
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Feb 5, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion